P075 Hippo-Yap Pathway Mediated Resistance to Crizotinib in ROS1-Positive Lung Cancer

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.10.088
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Melatonin Protects Against Lung Fibrosis by Regulating the Hippo/Yap Pathway

International Journal of Molecular Sciences
Organic ChemistryMolecular BiologyTheoretical ChemistryInorganic ChemistryComputer Science ApplicationsSpectroscopyMedicineCatalysisPhysical
2018English

Clinicopathological Features and Clinical Efficacy of Crizotinib in Chinese Patients With ROS1‑positive Non‑small Cell Lung Cancer

Oncology Letters
Cancer ResearchOncology
2019English

Energy Stress Regulates the Hippo-Yap Pathway

Cancer Discovery
Oncology
2014English

P1.01-113 Analysis of Clinicopathological Features and Clinical Efficacy of Crizotinib in ROS1 Positive Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Hippo/Yap Signaling Pathway Is Involved in Osteosarcoma Chemoresistance

Chinese Journal of Cancer
2016English

Clinical Features of Bim Deletion Polymorphism and Its Relation With Crizotinib Primary Resistance in Chinese Patients With ALK /ROS1 Fusion-Positive Non-Small Cell Lung Cancer

Cancer
Cancer ResearchOncology
2017English

The Hippo Pathway Transcriptional Co-Activator, YAP, Confers Resistance to Cisplatin in Human Oral Squamous Cell Carcinoma

International Journal of Oncology
Cancer ResearchOncology
2015English

Crizotinib Improves Osteoarthritis Symptoms in a ROS1-Fusion Advanced Non–Small Cell Lung Cancer Patient

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2015English

YAP Activates the Hippo Pathway in a Negative Feedback Loop

Cell Research
Cell BiologyMolecular Biology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy